Are SkyePharma PLC And Spire Healthcare Group PLC Better Buys Than Shire PLC And BTG plc?

Should you buy a slice of SkyePharma PLC (LON: SKP) and Spire Healthcare Group PLC (LON: SPI) ahead of Shire PLC (LON: SHP) and BTG plc (LON: BTG)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in SkyePharma (LSE: SKP) and Spire Healthcare (LSE: SPI) are down by 5% and 4% today despite releasing results that were in line with expectations. And, even though both companies have bottom lines that are not particularly impressive, they continue to have upbeat forecasts for the next couple of years. Is this enough, though, to make them more attractive buys than fellow healthcare companies, Shire (LSE: SHP) (NASDAQ: SHPG.US) and BTG (LSE: BTG)?

Results

In the case of SkyePharma, it remains confident regarding its medium term outlook, despite losses widening in 2014 versus 2013. In fact, the drug development company is anticipating a step change in revenue growth during the course of the year, as a number of products launched in recent years are expected to deliver significant top line improvements for the company. Furthermore, 2014’s revenue figure was hit hard by an exceptional cost of £26.6m resulting from the repayment of bonds and restructuring at a manufacturing site, thereby making its results appear more disappointing than they perhaps were.

Meanwhile, Spire Healthcare was hit by reductions in the NHS tariff applicable during the course of 2014, which meant that its reported net profit fell from £102m in 2013 to just £6m in 2014. However, its future could be much more upbeat, with it receiving planning consent to open new hospitals in Manchester and Nottingham, as well as a radiotherapy centre in Essex. And, with Spire Healthcare being well capitalised, it seems poised to capture an increasing share of the UK’s growing independent healthcare market.

Looking Ahead

As mentioned, both SkyePharma and Spire Healthcare are set to post improved figures over the next couple of years. However, much of this appears to already be priced in, with Spire Healthcare trading on a price to earnings growth (PEG) ratio of 4.6, and SkyePharma’s PEG ratio also being high at 3.1. As such, their share prices may come under further pressure even if they are able to deliver on their upbeat forecasts.

This situation contrasts markedly with that of Shire and BTG. For example, Shire has a PEG ratio of 1.2, while BTG’s is just 0.5 – both of which indicate good value and that the two companies’ share prices could move much higher. And, with both stocks being highly profitable at the present time and having relatively strong track records of earnings growth, they appear to be much more appealing investments than SkyePharma and Spire.

Certainly, all four stocks are likely to remain volatile compared to the wider index but, even with this volatility being taken into account, BTG and Shire seem to be worth buying right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »